Resumen: Since amyotrophic lateral sclerosis (ALS) was discovered and described in 1869 as a neurodegenerative disease in which motor neuron death is induced, a wide range of biomarkers have been selected to identify therapeutic targets. ALS shares altered molecular pathways with other neurodegenerative diseases, such as Alzheimer’s, Huntington’s, and Parkinson’s diseases. However, the molecular targets that directly influence its aggressive nature remain unknown.What is the first link in the neurodegenerative chain of ALS that makes this disease so peculiar? In this review, we will discuss the progression of the disease from the viewpoint of the potential biomarkers described to date in human and animal model samples. Finally, we will consider potential therapeutic strategies for ALS treatment and future, innovative perspectives.Idioma: InglésDOI: 10.1155/2014/925101Año: 2014Publicado en: BioMed Research International 2014 (2014), 925101 [12 pp]ISSN: 2314-6133Factor impacto JCR: 1.579 (2014)Categ. JCR: MEDICINE, RESEARCH & EXPERIMENTALrank: 85 / 123 = 0.691 (2014) - Q3 - T3 Categ. JCR: BIOTECHNOLOGY & APPLIED MICROBIOLOGYrank: 106 / 162 = 0.654 (2014) - Q3 - T2 Factor impacto SCIMAGO: